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High frequency of the 
exoU+/exoS+ genotype associated 
with multidrug-resistant “high-risk 
clones” of Pseudomonas aeruginosa 
clinical isolates from peruvian 
hospitals
Gertrudis Horna  1,2,3, Catherine Amaro4, Aida palacios4, Humberto Guerra  3 & 
Joaquim Ruiz  1,5
the type III secretion system of Pseudomonas aeruginosa is an important virulence factor contributing 
to the cytotoxicity and the invasion process of this microorganism. the current study aimed to 
determine the presence of the exoU+/exoS+ genotype in P. aeruginosa clinical isolates. the presence 
of exoS, exoT, exoU and exoY was determined in 189 P. aeruginosa by PCR, and the presence/absence 
of exoU was analysed according to source infection, clonal relationships, biofilm formation, motility 
and antimicrobial susceptibility. The gyrA, parC, oprD, efflux pump regulators and β-lactamases genes 
were also analysed by PCR/sequencing. The exoS, exoT and exoY genes were found in 100% of the 
isolates. Meanwhile, exoU was present in 43/189 (22.8%) of the isolates, being significantly associated 
with multidrug resistance, extensively drug resistance as well as with higher level quinolone resistance. 
However, the presence of β-lactamases, mutations in gyrA and parC, and relevant modifications in 
efflux pumps and OprD were not significantly associated with exoU+ isolates. MLst analysis of a 
subset of 25 isolates showed 8 different STs displaying the exoU+/exoS+ genotype. The MDR basis 
of the exoU+ isolates remain to be elucidated. Furthermore, the clinical implications and spread of 
exoU+/exoS+ P. aeruginosa isolates need to be established.
Pseudomonas aeruginosa is a Gram-negative pathogen causing opportunistic infections in susceptible hosts. It 
is a leading cause of acute pneumonia in hospitalised patients and is responsible for chronic lung infections in 
patients with cystic fibrosis1. One of the reasons for the poor clinical outcomes of P. aeruginosa infections is 
thought to be virulence factors, especially the Type III secretion system (T3SS) which is considered an important 
contributor to cytotoxicity and the invasion process2–4. This system allows these bacteria to directly inject effector 
proteins into eukaryotic cells. At present, four effector proteins have been identified: ExoU, a phospholipase; 
ExoY, an adenylate cyclase; and ExoS and ExoT, which are bifunctional proteins. ExoT and ExoY are encoded by 
almost all strains, therefore might be considered an inevitable component of P. aeruginosa virulence5. ExoS and 
ExoU contribute greatly to pathogenesis. Thus, ExoU is responsible for a highly cytotoxic phenotype which leads 
to host cell death and is considered to be a relevant factor involved in the severity of infections and as an inde-
pendent factor of early mortality during blood infections6–8. Furthermore, it has been shown that the exoU gene 
is a key factor in the early stages of P. aeruginosa pneumonia9. Meanwhile, the distribution of the genes encoding 
these effectors is not uniform and some, particularly exoS and exoU, are almost always mutually exclusive5,7,10–12. 
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probably because these genes provide enhanced fitness in distinct ecological niches13. However, some reports 
have shown the concomitant presence of both genes in a significant number of clinical isolates14–16.
In recent years, the incidence of multidrug resistance (MDR) especially to fluoroquinolones (FQs) and carbap-
enems, has increased, becoming a major issue for nosocomial infection by P. aeruginosa. In this microorganism, 
the mechanisms of resistance to FQs are mainly chromosomal such as the presence of target-site gene mutations 
(TSMs) or increased production of resistance–nodulation–cell division (RND) type efflux pumps4,17. However, 
quinolone resistance transferable determinants such as the presence of qnr or crpP genes have been reported18,19. 
On the other hand, the most frequent mechanisms of resistance to carbapenems include the inactivation of OprD, 
the increased production of multidrug efflux pumps, and hydrolysis by carbapenemases4,17.
Several studies have reported the relationship between the presence of the exoU gene and MDR in clinical 
isolates of P. aeruginosa3,4,15,20. However, the concomitant presence of the exoU+ and exoS+ genes has scarcely 
been reported due to the frequent mutual exclusion of the two genes. Therefore, this study aimed to determine 
the presence of the exoU+/exoS+ genotype and its association with phenotypic characteristics, resistance genes 
related to MDR and efflux pump regulators in clinical isolates of P. aeruginosa.
Results
Bacterial isolates and distribution of genes encoding T3SS. The exoS, exoT and exoY genes were 
found in 100% of the isolates studied. Meanwhile, the exoU gene was present in 43/189 (22.8%) of the isolates, 
Therefore, all isolates presenting the exoU+ gene were exoU+/exoS+.
No unspecific annealing of the primers was detected during the in silico analysis, thereby ruling out the possi-
bility of false priming. On the other hand, the high prevalence of exoU+ genotype isolates was not related to the 
spread of a unique BOX-pattern. Thus, exoU+ isolates were classified within 25 different BOX groups. Sixteen 
BOX-patterns contained both exoU+ and exoU− genes (Supplementary Figure). The results were fully validated 
by the sequencing of exoU and exoS amplicons in 25 isolates (one for each BOX group).
exoU+/exoS+ genotype and hospital wards. The exoU gene was detected in 23/77 (53.4%) of the iso-
lates from Hospital Arzobispo Loayza (HAL) and in 20/112 isolates (46.5%) of isolates from Hospital Nacional 
Cayetano Heredia (HNCH), bordering but without reaching significant differences (p = 0.0529).
Fifty-three P. aeruginosa had no data about hospital ward origin. The analysis of the remaining 136 isolates 
showed that exoU was more frequent among P. aeruginosa from patients attending Intensive Care Units (ICUs) 
[9/18 (50.0%) p = 0.0197] and the burn ward (6/8, 75.0%, p = 0.0019). Nonetheless, the presence of exoU was not 
specifically associated with any source of infection (Tables 1 and 2).
Characteristics exoU+/exoS+ exoU−/exoS+
Number of isolates = 189 43 146
HNCH isolates = 112 20 (46.5%) 92 (63.0%)
HAL isolates = 77 23 (53.4%) 54 (36.9%)
Bronchial secretions 72/189 15 (34.8%) 57 (39.0%)
Wounds/
abscesses = 33/189 10 (23.2%) 23 (15.7%)
Urine = 55/189 13 (30.2%) 42 (28.7%)
Other = 29/189 5 (11.6%) 24 (16.4%)
SBP = 78 14 (32.5%) 64 (43.8%)
Presence of twitching = 163 38 (88.3%) 125 (85.6%)
Presence of 
swarming = 109 21(48.8%) 88 (60.2%)
Presence of 
swimming = 157 36 (83.7%) 121 (82.8%)
Table 1. Distribution of the exoU+/exoS+ genotype among the isolates analyzed. HNCH: Hospital Nacional 
Cayetano Heredia, HAL: Hospital Arzobispo Loayza, SBP: Strong biofilm producer. In no case were observed 
significant differences.
Ward n = 189 exoU+/exoS+ exoU−/exoS+
ICU 18 9 (50.0%)b 9 (50.0%)
Burnsa 8 6 (75.0%)c 2 (25.0)
External 28 9 (32.1%) 19 (67.9%)
Other 82 13 (15.9%) 69 (84.1%)
ND 53 6 (12.8%) 47 (87.2)
Table 2. Hospital ward origin of Pseudomonas aeruginosa isolates. ICU: Intensive Care Units; Externa: Samples 
belonging to hospital outpatients; ND: Isolates from which no specific hospital ward data was recorded, thus 
these isolates have not been included in the statiscal analysis; Other: All remaining hospitalisation wards. 
aAll burn patients were from Hospital Arzobispo Loayza. bSignificant number of exoU+ isolates (p = 0.0197). 
cSignificant number of exoU+ isolates (p = 0.0017).
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exoU+/exoS+ genotype and biofilm production and bacterial motility. On analysing the associ-
ation of the presence of exoU+/exoS+ genotype with other bacterial characteristics, it was observed that 42/43 
(97.7%) exoU+/exoS+ and 142/146 (97.3%) exoU−/exoS+ isolates were able to form biofilm, although no sig-
nificant association with strong biofilm production was detected. Thus 14/43 (32.5%) exoU+ isolates presented 
strong biofilm production (SBP), while 64/146 (43.8%) exoU− isolates presented the SBP phenotype (Table 1). 
With respect to bacterial motility, there was no significant association between exoU and the motility phenotype; 
however, 88.3%, 83.7% and 48.8% exoU+ isolates presented twitching, swimming and swarming, respectively 
(Table 1).
exoU+/exoS+ genotype and antimicrobial resistance. The exoU+ genotype was more likely 
to be found in FQ and aminoglycoside non-susceptible than susceptible isolates. Thus, 35/43 (81.4%) FQ 
non-susceptible isolates showed the presence of the exoU gene (p = 0.000256) (Fig. 1). Similarly, 30/43 (69.8%) 
of the exoU+ isolates were non-susceptible to aminoglycosides (p = 0.001246). On the other hand, although not 
significant, the exoU+ isolates were more resistant to cephalosporins and carbapenems. Thus, 24/43 (55.9%) and 
27/43 (62.8%) of the isolates displaying the exoU+ genotype were non-susceptible to these antimicrobial classes, 
respectively (Table 3).
On analysing the resistance levels to specific antibacterial agents, the exoU+ isolates were related to higher 
levels of resistance to all the FQs (levofloxacin - LVX; 81.4%, p = 0.000029; ofloxacin - OFX: 81.4%, p = 0.000191; 
ciprofloxacin - CIP: 76.7%. p = 0.000148) and monobactams (aztreonam: 69.8%, p = 0.000277) tested, as well as 
several aminoglycosides (gentamicin: 65.1%, p = 0.005514 and amikacin: 60.5%, p = 0.004749) and carbapen-
ems (meropenem: 62.8%, p = 0.015202). Overall, 33 out of 43 exoU+ isolates were classified as MDR or XDR 
[extensively drug-resistant] (p = 0.000108). Thus, the presence of exoU was associated with both MDR (20.9%, 
p = 0.019749) and XDR (55.8%, p = 0.013893) isolates. On the other hand, the absence of exoU was associ-
ated with pan-susceptible (PS) and moderately drug-resistant (MR) isolates (34.2%, p = 0.024049 and 22.6%, 
p = 0.021821 respectively) [Table 3]. All the isolates were susceptible to colistin.
exoU+/exoS+ genotype and non-susceptibility to fluoroquinolones. To further evaluate the cor-
relation between the level of susceptibility to FQ and the T3SS genotype, the presence of the exoU+ genotype 
regarding distribution of the MIC of LVX, OFX and CIP was determined (Fig. 2). The results showed that the pres-
ence of exoU+ was significantly more frequent among isolates with a high level of resistance (MIC > 128 mg/L) to 
LVX/OFX (p = 0.002818/p = 0.004902 respectively) and to CIP (MIC > 64 mg/L; p = 0.000191), while no differ-
ences were found between exoU+ and exoU− genotypes regarding low or moderate resistance levels to any of the 
FQ tested. On the other hand, exoU− isolates were associated with FQ susceptibility [LVX/OFX (MIC < 2 mg/L; 
p-values: 0.001596/0.003488) and CIP (MIC < 1 mg/L; p = 0.000859)] (Fig. 2).
exoU+/exoS+ genotype and mutations in target genes of QRDR. The gyrA and parC QRDR 
regions were amplified and sequenced in a subset of 50 isolates; 13/43 (30.2%) exoU+ and 37/146 (25.3%) exoU− 
(Table 4). Of these, 2 exoU+ and 14 exoU− isolates had no TSM. However, 5 of these 14 exoU− isolates (1094, 
1104, 1117, 1120 and 1121) displayed resistance to at least one of the FQs tested.
Similar proportions of single TSM were observed between exoU+ and exoU− isolates. Thus 2/13 (15.3%) 
exoU+ and 5/37 (13.5%) exoU− isolates possessed a single TSM. Meanwhile, 9/13 (69.2%) of exoU+ and 18/37 
(48.6%) of exoU− isolates possess multiple TSMs (Tables 4 and 5).
Overall, 34 isolates with mutations in gyrA and/or parC showed resistance to at least one FQ. The most fre-
quent amino acid substitutions were T83I and S87L at GyrA and ParC respectively, which were concomitantly 
found in 24 isolates, and only GyrA T83I was found in 2 isolates and ParC S87L in another 3 isolates. In addition, 
one isolate showed the amino acid codon substitution D87N in the gyrA gene, and another presented the double 
substitution D87N in GyrA and S87L in ParC. Meanwhile two isolates concomitantly presented 2 amino acid 
codon substitutions in gyrA (T83I/D87N) and one in parC (S87L) showing high MICs to all FQs. Finally, one 
isolate having the GyrA substitution E153K was detected, showing moderate resistance levels to FQ.
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Figure 1. Levels of non-susceptibility to fluoroquinolones in exoU+/exoU− isolates. FQ: Fluoroquinolones; 
*p = 0.000256.
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exoU+/exoS+ genotype and gene regulators of efflux pumps. The analysis of the MexAB-OprM 
regulators genes (mexR, nalC and nalD) showed the presence of 5/13 (38.5%) relevant and 8/13 (61.5%) irrelevant 
modifications in the exoU+ isolates. Meanwhile these regulators genes showed relevant and irrelevant modifica-
tions in the 21/37 (56.7%) and 16/37 (43.2%) of the exoU− isolates respectively.
The analysis of the MexEF-OprN regulators shown a similar scenario. Thus, 4/13 (30.7%) and 9/13 (69.2%) 
of the exoU+ displayed relevant and irrelevant modifications in mexS and mexT respectively. In the same way 
19/37 (51.3%) of relevant and 18/37 (48.6%) of irrelevant modifications were detected among exoU− isolates. 
Interestingly, the five exoU− isolates (1094, 1104, 1117, 1120, 1121) showing resistance to at least one of the FQs 
tested in the absence of TSM possess relevant modifications in the mexS gene, and also in nalC (isolate 1094) and 
mexR (isolate 1121).
Forty-seven out of 50 isolates (94%) showed irrelevant modifications in mexZ (a regulator of MexXY-OprM). 
Regarding MexCD-OprJ, no isolate showed alterations in the nfxB gene (Tables 4 and 5).
exoU+/exoS+  genotype and β-lactamases. Overall, 67 isolates suspected of carrying 
metallo-β-lactamases and/or serine-carbapenemases were phenotypically detected: 22 metallo-β-lactamases, 39 
serine-carbapenemases and 6 with both metallo-β-lactamases and serine-carbapenemases. It was of note that 4 
of these isolates were susceptible to both imipenem and meropenem. PCR results showed that the blaGIM, blaSIM, 
blaSPM, blaVIM genes and blaIMI and blaKPC corresponding to metallo-β-lactamases and serine-carbapenemases, 
respectively were not found in any isolate. All isolates suspected of carrying metallo-β-lactamases presented 
blaIMP while those which were positive for serine-carbapenemases possessed blaGES. All the exoU+ isolates 
showed a higher proportion of blaGES 32.5% (14/43) than blaIMP 9.30% (4/43), however no differences were 
observed (p = 0.246). In contrast, the exoU− isolates showed similar proportions of both genes [blaGES 21.2% 
(31/146) vs. blaIMP 16.4% (24/146); p = 0.125].
exoU+/exoS+ genotype and oprD gene. Neither relevant nor irrelevant modifications in the oprD gene 
were associated with the presence of exoU. Thus, in the oprD gene of exoU+ isolates were detected 7/13 (53.8%) 
and 6/13 (46.1%) relevant and irrelevant modifications respectively. Meanwhile, 17/37 (45.9%) and 20/37 (54.0%) 
exoU− isolates showed relevant and irrelevant modifications in oprD gene (Tables 4 and 5).
Antimicrobial 
Agents
Total (n = 189)
exoU+/exoS+ 
(n = 43)
exoU−/exoS+ 
(n = 146) P value
Cephalosporins 55.8 39.7 0.061364
   CAZ 44.2 37.0 0.394074
   FEP 55.8 39.0 0.050771
Monobactam
   ATM 69.8 38.4 0.000277
β-lactam + inhibitors
   PTZ 41.9 32.9 0.277429
Carbapenems 62.8 48.6 0,102388
   IMI 60.5 47.9 0.148927
   MER 62.8 41.8 0.015202
Aminoglycosides 69.8 41.8 0.001246
   GM 65.1 41.1 0.005514
   TO 34.9 41.1 0.464281
   AK 60.5 36.3 0.004749
Fluoroquinolones 81.4 50.0 0.000256
   CIP 76.7 43.8 0.000148
   LVX 81.4 45.2 0.000029
   OFX 81.4 49.3 0.000191
Polymyxins 0 0 —
   COL 0 0 —
PS 16.3 34.2 0.024049
   MR 7.0 22.6 0.021821
   MDR 20.9 8.2 0.019749
   XDR 55.8 34.9 0.013893
MDR + XDR 76.7 43.1 0.000108
Table 3. Percentage of antimicrobial resistance of Pseudomonas aeruginosa isolates. CAZ: Ceftazidime, 
FEP: Cefepime, ATM: Aztreonam, PTZ: Piperacillin/Tazobactam, IMI: Imipenem, MER: Meropenem, GM: 
Gentamicin, TO: Tobramicin, AK: Amikacin, CIP: Ciprofloxacin, LVX: Levofloxacin, OFX: Ofloxacin. PS: Pan-
susceptible. MR: Moderately drug-resistant; MDR: Multi drug-resistant. XDR: Extensively drug-resistant. The 
significant differences are highlighted in bold.
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exoU+/exoS+ genotype and multi-locus sequence typing (MLST). MLST analysis showed the 
presence of 16 different sequence types (STs) among the analysed subset of 25 P. aeruginosa isolates analysed, 
with 13 exoU+ isolates distributed in 8 different ST patterns. Of these, ST235 and ST357 were the most frequently 
found. ST235 was detected in 6 isolates from HNCH, with 5 isolates being exoU+ (2 XDR, 2 MDR and 1 MR) and 
1 exoU− (MR). ST357 was detected in 5 isolates from HAL, all being XDR and only susceptible to colistin and 
with two presenting the exoU gene. Furthermore, five new STs were found in the present study (ST3300, ST3301, 
ST3302, ST3303, and ST3305) two (ST3300 and ST3303) being exoU+ [Table 6].
Discussion
This study aimed to determine the presence of the exoU+/exoS+ genotype and its association with different phe-
notypic and genetic characteristics, with special emphasis on MDR levels and the underlying mechanisms and 
efflux pump regulators in clinical isolates of P. aeruginosa. The exoU gene was present in 22.7% of our isolates, 
with a trend to be more frequent among HAL isolates, which might be explained because the observed association 
of exoU genotype with patients attending to burn ward (all from HAL). Nonetheless, the exoU+ P. aeruginosa 
showed no association with a specific source of infection. Other studies have reported that this gene was present 
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Figure 2. Association between fluoroquinolone MIC levels and exoU+/exoU− isolates. Only significant 
differences are reported. (a) Differences in the levofloxacin MIC levels between exoU+ and exoU− isolates. 
S: Susceptible (MIC ≤ 2 mg/L; p = 0.001596); I: Intermediate (MIC of 4 mg/L); LR: Low Resistance Levels 
(MIC of 8–16 mg/L); MR: Moderate Resistance Levels (MIC of 32–64 mg/L); HR: High Resistance Levels 
(MIC > 128 mg/L; p = 0.002818). (b) Differences in the ofloxacin MIC levels between exoU+ and exoU− 
isolates. S: Susceptible (MIC ≤ 2 µg/ml; p = 0.003488); I: Intermediate (MIC of 4 µg/ml); LR: Low Resistance 
Levels (MIC of 8–16 mg/L); MR: Moderate Resistance Levels (MIC of 32–64 mg/L); HR: High Resistance Levels 
(MIC > 128 mg/L; p = 0.004902). (c) Differences in the ciprofloxacin MIC levels between exoU+ and exoU− 
isolates. S: Susceptible (MIC ≤ 1 mg/L; p = 0.000859); I: Intermediate (MIC of 2 mg/L); LR: Low Resistance 
Levels (MIC of 4–8 mg/L); MR: Moderate Resistance Levels (MIC of 16–32 mg/L); HR: High Resistance Levels 
(MIC > 64 mg/L; p = 0.000191).
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in 28–42% of P. aeruginosa isolates causing acute infections, being especially related to pneumonia and respira-
tory infections8,11,20,21.
On the other hand, in the current study the presence of the exoS, exoT and exoY genes was found in 100% 
of the isolates. Similar results were reported for other studies in which the prevalence of these genes varied 
from 58–72% for exoS, for 89% of exoY, for 92–100% of exoT11,22. Interestingly, previous studies have shown 
the mutual exclusion of the exoU and exoS genes5,7,10,11. However, few studies have reported the concomitant 
presence of both genes in association with acute infection, being for instance detected in 40 out of 60 (67%) 
isolates of P. aeruginosa from bacteremia, belonging to 42 different pulse-field gel electrophoresis patterns16. 
The clonal relationships among the current analysed isolates were previously determined by Horna et al.23, with 
the 189 P. aeruginosa distributed in 72 different BOX-patterns; of these, 27 BOX-patterns were represented by 
a single isolate and the remaining 45 BOX-patterns including up to 14 isolates23. The exoU+/exoS+ genotypes 
detected in our study were distributed within 25 out of these 72 different BOX-patterns, therefore, as in the study 
of Morales-Espinosa16, the current results do not represent the spread of a successful local clone. In addition, the 
presence of 16 BOX-patterns containing both exoU+ and exoU− genotypes suggests genetic events of acquisi-
tion/loss of the exoU encoding genomic islands and of intraspecies diversity due to the dynamic nature of the 
accessory genome of this microorganism24–26. Analysis of MLST patterns in a subset of 25 isolates, also showed 
high clonal heterogeneity, even in the exoU+ isolates. In addition, 2 of these ST (ST235 and ST357) had for both 
exoU+ and exoU− isolates. Although unusual, the presence of the exoU−/exoS+ genotype in isolates belonging 
to ST235 has also been previously described27. This finding agrees with the proposed events of acquisition/loss 
of the exoU gene. Furthermore, the present results support the proposed P. aeruginosa non-clonal epidemic 
population structure28, both highlighting the presence of several high-risk clones (such as ST235 and ST357) 
with a worldwide distribution12,25,29, and also showing the presence of a number of undescribed P. aeruginosa ST 
patterns in under studied geographical areas.
It has been proposed that P. aeruginosa possessing swarming motility are more prone to presenting T3SS30, 
and some authors have related the presence of swarming and swimming as well as that of exoU to higher viru-
lence31. Nonetheless, in our study, no specific association was observed between the presence of the exoU+ gen-
otype and motility. Regarding biofilm formation, Azimi et al. showed that only 2.5% of the isolates presenting the 
exoU and exoS genes were biofilm producers and that all non-biofilm producer isolates presented the exoU and/or 
exoS genes32. In agreement with this finding, although only 1/43 exoU+/exoS+ genotype isolates were unable to 
form biofilm, the present results did not show an association between the presence of exoU and SBP.
Some studies have reported that the exoU+/exoS− genotype was found to be significantly associated with 
MDR compared to the exoU−/exoS+ genotype1,2,4,33. This relationship was not observed in our study, since the 
exoS gene was found in all the isolates. However, the exoU+ isolates were significantly associated with MDR and 
XDR when compared to exoU− isolates. This association between the exoU genotype and the MDR/XDR phe-
notypes may be due to the presence of transferable antibiotic-resistant determinants such as integrons carrying 
mobile gene cassettes within the accessory genome of exoU+ P. aeruginosa25,34.
In agreement with other studies, here, the presence of the exoU genotype was associated with increased levels 
of FQ resistance as well as with P. aeruginosa isolates displaying high MIC levels to this antimicrobial class1,2,4,22. 
Similar to Agnello et al.35, the present results agree that the development of high level of resistance to FQ has a 
lower fitness cost on exoU+ compared to exoU− P. aeruginosa isolates. Of note, the emergence of the exoU+ 
ST235, established around 198429, coincides with the beginning of the use of FQ36, suggesting that the worldwide 
dissemination of this (and other) exoU+ ST has been favoured by this lack of deleterious effect on fitness of 
selected QRDR mutations29.
In agreement with other studies, the most frequent mutations were found in the amino acid codon 83 (T83I) and/or 
87 (D87N) of gyrA and 87 (S87L) of parC1. In addition, a higher proportion of multiple TSM in gyrA and parC was 
found in exoU+ than in exoU− isolates. However, these were not significantly different, as also previously reported 
by Takata et al.4. Three resistant isolates had a single mutation in parC showing that a previous gyrA mutation is not a 
strict requisite for the acquisition of mutations at other target genes leading to resistance1. Finally, one isolate showed 
exoU+ 
(n = 13)%
exoU− 
(n = 37)% P value
TSM single 2 (15.3) 5 (13.5) 0.867
TSM multiple 9 (69.2) 18 (48.6) 0.200
MexAB - RM 5 (38.5) 21 (56.7)
0.256
MexAB - IM 8 (61.5) 16 (43.2)
MexEF- RM 4 (30.7) 19 (51.3)
0.200
MexEF- IM 9 (69.2) 18 (48.6)
MexXY - RM 1 (7.70) 2 (5.40)
0.765
MexXY - IM 12 (92.3) 35 (94.6)
oprD - RM 7 (53.8) 17 (45.9)
0.623
oprD - IM 6 (46.1) 20 (54.0)
Table 4. Distribution of exoU+/exoS+ genotype according to the gyrA/parC QRDR, oprD gene and efflux 
pumps regulators. TSM: Target Site Mutation RM: Relevant Modification; IM: Irrelevant Modification. No 
alteration was found on nfxB (MexCD regulator).
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exoU 
Genotype Isolates gyrA parC nalD nalC mexR nfxB mexZ mexS mexT
FQ MIC (mg/L)
oprD IMI MERLVX OFX CIP
exoU+ 1069 — — — G71E — — — NA-c — 0.5 2 0.5 2 S S
exoU+ 1070 T83I S87L ∆nt397-398 G71E,S209R V126E — L105R — — 64 128 32 W65* + 2 R R
exoU+ 1071 T83I S87L — G71E,S209R V126E — L105R — — 64 128 32 W65* + 2 R R
exoU+ 1072 T83I S87L NA G71E,S209R V126E,L131P — L105R NA-b — 64 128 64 NA R R
exoU+ 1073 E153K — R44P G71E,S209R,A145V V126E — L105R,R167S — — 32 64 8 3 S S
exoU+ 1074 — — — G71E,S209R V126E — NA NA-c — 1 2 0.5 3 S S
exoU+ 1075 T83I S87L — G71E,S209R,D79E V126E — G56S V73A — 16 64 16 3 R R
exoU+ 1076 — S87L — G71E,S209R — — — — — 128 >256 128 T103S,K115T,F170L, E185Q,P186G,V189T,G307D R R
exoU+ 1077 T83I S87L — G71E,S209R V126E — — — — 64 32 64 insnt 1201-1205 (GTCCA) + 3 R R
exoU+ 1078 T83I S87L ∆nt 263-279 — V126E — — — — 128 256 64 insnt 1201-1205 (GTCCA) + 3 R R
exoU+ 1079 T83I/D87N S87L ∆nt 263-279 G71E,S209R V126E — — — — 256 256 256 3 S S
exoU+ 1080 T83I S87L ∆nt 263-279 G71E,S209R V126E — — NA-b - 64 128 64 insnt 1201-1205 (GTCCA) + 3 R R
exoU+ 1081 T83I S87L L194R G71E,S209R V126E — — — — 64 256 64 3 S S
exoU− 1082 — — — G71E,S209R — — — — NA 0.5 1 0.5 4 S S
exoU− 1084 T83I S87L NA G71E,A145V,S209R — — — NA-c P185R 128 256 64 insnt941–942(GC) R R
exoU− 1085 T83I S87L ∆nt451-461 G71E,S209R — — Y18C NA-c — 128 256 128 — S S
exoU− 1086 T83I S87L ∆nt 397-398 G71E,S209R V126E — ∆AA F103-V112 — — 64 128 64 insnt678 (G) + C R R
exoU− 1087 — — — NA V126E — L105R NA-c — 1 2 0.25 3 R S
exoU− 1088 — — — NA V126E — — NA-c NA 0.5 1 0.5 2 S S
exoU− 1089 T83I S87L ∆nt 397-398 G71E,S209R V126E — L105R — — 128 128 32 2 R R
exoU− 1092 D87N S87L 1 G71E,S209R V126E — S66L — — 4 4 2 NA S S
exoU− 1093 T83I — ∆nt 397-398 G71E,S209R V126E — L105R — — 64 256 32 NA R R
exoU− 1094 — — — ∆nt234-243 + G71E,Q81P — — — NA-b — 4 16 0.5 2 S S
exoU− 1095 T83I S87L — G71E,S209R NA — H18Y NA-b — 64 64 32 Y49* + 4 R R
exoU− 1096 T83I S87L ∆nt 391 G71E,S209R V126E — V72L G224S — 128 128 64 V127L S S
exoU- 1097 — — ∆nt 391 G71E,S209R — — — NA-b — 4 2 0.25 3 S S
exoU− 1098 — — T188A G71E,S209R,P210L — — Q21* — — 1 1 1 insnt 605-609 (CAACA) + 4 R S
exoU− 1100 T83I S87L — G71E,S209R NA — H18Y — — 64 128 32 Y49* + 4 R R
exoU− 1102 T83I S87L — G71E,S209R V126E — H18Y — — 16 64 8 Y49* + 4 R R
exoU− 1103 — — — G71E,A186T — — E124K — — 2 2 0.25 NA S S
exoU− 1104 — — — G71E,S209R L131P — — NA-c — 8 32 32 4 R R
exoU− 1105 T83I S87L ∆nt 397-398 G71E,S209R V126E — L105R — — 64 64 32 W65* + 2 R R
exoU− 1106 — S87L — — NA — ∆nt408-409 NA-c — 4 2 1 — S S
exoU− 1107 — — — G71E,S209R,P210L NA — L95M NA-c D290E 2 2 0.5 4 S S
exoU− 1108 — — T188A G71E,S209R — — — — — 0.5 2 0.5 3 S S
exoU− 1109 — — — G71E,S209R,D79E — — — — NA 0.5 1 0.5 4 S S
exoU− 1110 T83I S87L — G71E,S209R — — — — P185R 128 256 128 insnt941–942(GC) R S
exoU− 1111 T83I S87L — — NA — H18Y NA-b — 128  > 256 128 Y49* + 4 R R
exoU− 1112 T83I S87L — G71E,S209R NA — H18Y NA-b — 64 128 64 Y49* + 4 R R
exoU− 1113 T83I S87L ∆nt 397-398 G71E,S209R V126E — L105R — — 128 128 32 W65* + 2 R R
exoU− 1114 — S87L — G71E,S209R — — — — — 16 32 16 4 S S
exoU− 1115 T83I S87L — G71E,S209R — — — — — 32 64 32 4 S S
exoU− 1116 T83I S87L — G71E,S209R — — — — — 32 64 32 4 S S
exoU− 1117 — — — — — — — NA-c — 16 4 0.25 4 S S
exoU− 1118 T83I/D87N S87L ∆nt 263-279 G71E,S209R V126E — — — — 128 >256 >256 3 S S
exoU− 1119 T83I — — S209R V126E — — NA-b — 8 16 4 4 S S
exoU− 1120 — — — G71E,S209R V126E — — NA-d — 8 4 2 4 S S
exoU− 1121 — — — G71E,S209R NA — L141Q NA-c — 8 64 1 insnt1087(A) + ∆nt 
1294(T) + T103S,K115T,F170L
R R
exoU− 1122 D87N — — G71E,S209R — — — NA-c — 64 64 64 Y49* + 4 R R
exoU− 1123 T83I S87L — G71E,S209R NA — H18Y — — 64 128 32 Y49* + 4 R R
Table 5. Modifications in target genes of the QRDR, efflux pump regulators, the oprD gene and antimicrobial 
susceptibility to fluoroquinolones and carbapenems in exoU+ and exoU− isolates. The symbol “−” represent 
wild type isolates; NA: No amplification; the symbol ∆nt represents nucleotide deletion being noted the first 
and last nucleotides deleted; the symbol ∆AA represents amino acid deletions being noted the first and last 
amino acid deleted; insnt: nucleotide insertion; The symbol “*” represents codon STOP. FQ-MIC: MIC to 
fluoroquinolones (LVX: Levofloxacin; OFX: Ofloxacin; CIP: Ciprofloxacin); IMI/MER are isolates showing 
susceptibility (S); resistance or intermediate susceptibility (R) to imipenem or meropenem performed by 
the disk diffusion assay. Alterations at nalC, nalD, mexR, mexS and mexT as well as the patterns of OprD 
were previously described17. The patterns of OprD are named accordingly to Horna et al.17. 1. Amino acid 
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an uncommonly reported substitution in GyrA (E153K) having moderate resistance to FQ (MIC LVX = 32 mg/L, 
OFX = 64 µg/mL and CIP = 8 mg/L). This mutation has been previously identified in a P. aeruginosa isolate hav-
ing a MIC of CIP of 8 mg/L and a concomitant amino acid change S87L in parC, and in two FQ-resistant unrelated 
Escherichia coli isolates, but neither data on MIC levels nor information of concomitant TSM was provided37,38.
P. aeruginosa has several RND-type efflux pumps, being MexAB-OprM, MexCD-OprJ, MexEF-OprN and 
MexXY-OprM efflux pumps well investigated39. In our study the exoU+ isolates showed higher proportions of irrel-
evant modifications in the regulators of MexAB-OprM and MexEF-OprN, and therefore these efflux pumps could 
presumably show normal basal expression levels. In agreement, in a previous study analysing mexA expression in a 
subset of isolates included in this study, those isolates having irrelevant modifications in MexAB-OprM regulators 
showed mexA expression levels equivalent to PAO1 and significant lowers (p = 0.02) than those reported in isolates 
having relevant modifications in these regulator genes17. Furthermore, this finding agrees with other studies showing 
that the isolates overexpressing mexB were less likely to be found among exoU+ isolates, and the overexpression of 
mexF and mexD was not correlated with the exoU+ genotype4. Although, in our study, almost all isolates showed the 
mexZ gene with irrelevant modifications (and as above may be considered as fully functional), it has been reported 
that the isolates overexpressing mexY were significantly associated with the exoU+ genotype4.
The 5 isolates possessing resistance to any of the FQ tested in the absence of a TSM were exoU−, further 
showing relevant alterations in at least one efflux pump regulator gene. Furthermore, data on 1094 isolate MexA 
and MexE expression levels were recorded in a previous study, showing increased mexA gene expression17. 
This finding suggests that in exoU− isolates FQ resistance will be more prone to be developed by mechanisms 
different to TSM supporting the proposed higher fitness cost of TSM in P. aeruginosa isolates presenting the 
exoU− genotype35.
Previous studies have reported that oprD mutations alone is the source of non-susceptibility to imipenem, 
and the mechanisms leading to meropenem resistance are thought to be multifactorial40. Although in a previous 
study an association between oprD defective mutations and the presence of exoU was observed4, this scenario 
was not found in the current study, also in agreement with the lack of association between exoU and imipenem 
non-susceptibility.
Regarding the presence of β-lactamases, non-conclusive associations were found, despite a higher proportion 
of blaGES being found in exoU+ isolates and blaIMP in the exoU− isolates. Likewise, Takata et al. did not find 
differences in the prevalence of blaIMP between exoU+ and exoU− isolates4. These data together suggest that 
the prevalence of specific transferable genes may be more related to the specific prevalence of the gene in the 
area analysed than with to specific exoenzyme genetic background. Furthermore, GES-type β-lactamases and 
IMP-metallo-carbapenemases have been widely reported in South America, including Peru23,41–43.
Overall, the association between the exoU+ genotype and MDR/XDR was shown, despite the presence of 
β-lactamase, mutations in gyrA and parC, relevant modification in efflux pumps and OprD not being signifi-
cantly associated with exoU+ isolates. Thus, the MDR/XDR phenotypic basis of the exoU+ genotype remains to 
be elucidated. One limitation of this study was that not all the mechanisms of resistance were determined, and 
therefore, other mechanisms might be correlated to MDR and exoU+ genotype.
Overall, these data suggest that exoU+ genotype might be genetically favoured in environments with high 
antibiotic pressure, such as ICUs10. In fact, it has been observed its adaptation to FQ-rich environment1. As has 
been commented above, the exoU+ isolates were more prone to be associated with ICU and burn wards, and 
subsequently with the most fragile patients of hospital environment. However, no data on background and final 
outcome of the patients was recorded, therefore lacking data about patient risk factors facilitating exoU+ P. 
aeruginosa infections, and information about patient mortality. Analysed together, these data agree with previous 
studies showing that exoU+ isolates were significantly found in man-made environmental sites while the exoS+ 
isolates were found in natural environmental sites13,44.
Regarding the ST detected, ST179, ST235, ST308, ST348, ST357 and ST699 are reported in the Pseudomonas 
aeruginosa MLST Database as having been previously described on different continents, being therefore widely 
disseminated45. ST235 and ST357 are among the most widespread high-risk clones. The results of the subset 
of isolates analysed agree with this distribution, being the two most frequently detected STs. Furthermore, the 
present data suggest a different hospital distribution of both STs. ST235 has been associated with a poor clinical 
outcome in part due to its high level of antibiotic resistance and the presence of the exoU+ gene12,29. Regarding 
antibiotic resistance, ST235 and ST357 are usually resistant to FQ, aminoglycosides and β-lactams12,25,46,47. 
Likewise, all the isolates belonging to these STs were at least MR, with all ST357 isolates being XDR and display-
ing resistance to all antibacterial agents tested except colistin. Regarding antibiotic resistance mechanisms, 3 out 
of 6 isolates belonging to ST235 (isolates 1077, 1078 and 1079) displayed the presence of blaGES and an additional 
isolate (isolate 1080) possessed blaIMP (Table 6). Similarly, the presence of blaGES and blaIMP was detected in 2 
(isolates 1093 and 1105) and 1 (isolate 1089) respectively, of the isolates belonging to the ST357. In addition, all 
ST235 and ST357 isolates identified showed the presence of QRDR mutations.
substitutions: Q134H, Q142H, A145P, D147H, E148K, C149R, H154P, R160K, D176E, D185Y, G206S, 
S209I. 2. oprD-Pattern C17: V127L, E185Q, P186G, V189T, E202Q, I210A, E230K, S240T, N262T, T276A, 
A281G, K296Q, Q301E, R310E, (±G312R), A315G, L347M, S403A, Q424E + 372V-DSSSSYAGL-383. 3. 
oprD-Pattern B17: T103S, K115T, F170L, E185Q, P186G, V189T, R310E, A315G, (±G425A). 4. oprD-Pattern 
A17: E202Q, I210A, E230K, S240T, N262T, A267S, A281G, K296Q, Q301E, R310G, (±V352I), V359L, 
(±Q424R) + 372V-DSSSSYAGL-383. NA-b: No amplification of mexS gene but amplification of N- and 
C-terminal regions. NA-c: No amplification of mexS gene but amplification of N-terminal region. NA-d: No 
amplification of mexS gene and no amplification of N- and C- terminal regions.
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The remaining exoU+ isolates belonged to ST308, ST348, ST759 and ST2726, as well as to the newly identified 
ST3300 and ST3303. Among these, the presence of exoU has been largely described on the high-risk clone ST308, 
which usually presents an MDR/XDR phenotype, related to a variety of molecular mechanisms including car-
bapenemases such as NDM48,49. On the other hand, ST641 has been previously reported in Korea in association 
with antimicrobial resistance and the exoU−/exoS+ genotype50. Data of the remaining STs are scarce, with ST179 
being the most well characterised. In the present study, ST179 was found in an MDR isolate from a bronchial 
secretion. Accordingly, this clone has been previously associated with MDR P. aeruginosa, causing chronic res-
piratory infections in Spanish hospitals51,52.
In conclusion, an unusual high number of unrelated clinical isolates of P. aeruginosa showing the exoU and 
exoS genes concomitantly were found, suggesting the presence of specific pressures which facilitate the stable 
presence of both genes and highlight their concomitant dissemination in the area studied. The exoU+/exoS+ 
were associated with MDR and XDR. Furthermore, these isolates showed an enhanced ability to acquire higher 
levels of FQ resistance, which might be related to lower fitness cost. Rapid diagnostic determination of viru-
lence genotypes and antibiotic resistant profiles as well as continuous surveillance are needed to monitor these 
high-risk P. aeruginosa isolates.
Material and Methods
study area. The Hospital Nacional Cayetano Heredia (HCNH) is a level III-1 hospital with 452 beds (includ-
ing a total of 24 in the ICUs, of these 6 beds belonging to a Neonatal ICU), which receives patients from around all 
the country53,54. The direct reference area is composed by the districts in the north of the city of Lima, the largest 
urban area of the capital, in which the population is heterogeneous: urban, rural and marginal urban. In 2011 the 
HCNH receives 147,642 outpatients, with 17,558 hospital admissions53. The Hospital Arzobispo Loayza (HAL) is 
also considered as a level III-1 hospital accounting for 806 beds (Of these 26 presents in ICUs)55. In addition, HAL 
acts as reference center for burn patients56. Its referral area comprises districts in the center of Lima, attending 
also population of other Lima districts and Peruvian areas, with a heterogeneous population: urban and urban 
marginal. In 2011 the HAL receives 218,123 outpatient visits (10.3% from outside of Lima), with 29,158 hospital 
admissions57. In 2014 the population of Lima was reportedly 9,752,000 inhabitants, 2,475,432 and 1,796,112 living 
in the north and center districts respectively58.
Isolates Hospital acsA aroE guaA mutL nuoD ppsA trpE ST
exoU 
genotype β-lactamases
Antimicrobial 
profile
Source of 
infections
1069 HNCH 6 10 5 3 4 3 112 2726 exoU+ − MR 5
1070 HNCH 2 4 5 3 1 6 11 357 exoU+ − XDR* 2
1071 HNCH 2 4 5 3 1 6 11 357 exoU+ − XDR* 3
1072 HNCH 16 4 5 3 1 6 10 3303 exoU+ ges like XDR 1
1073 HNCH 50 13 105 28 16 7 47 759 exoU+ − MDR 2
1074 HAL 28 5 4 5 4 38 167 3300 exoU+ − PS 1
1075 HAL 13 4 5 5 12 7 15 308 exoU+ ges like XDR* 1
1076 HAL 22 20 11 3 3 3 7 348 exoU+ ges like/imp like XDR 2
1077 HAL 38 11 3 13 1 2 4 235 exoU+ ges like XDR 3
1078 HAL 38 11 3 13 1 2 4 235 exoU+ ges like XDR 3
1079 HAL 38 11 3 13 1 2 4 235 exoU+ ges like MDR 2
1080 HAL 38 11 3 13 1 2 4 235 exoU+ imp like XDR 1
1081 HAL 38 11 3 13 1 2 4 235 exoU+ − MR 5
1089 HNCH 2 4 5 3 1 6 11 357 exoU− ges like/imp like XDR* 5
1093 HNCH 2 4 5 3 1 6 11 357 exoU− ges like XDR* 5
1094 HNCH 28 20 94 5 1 6 10 2118 exoU− − MR 1
1100 HNCH 36 27 28 3 4 13 7 179 exoU− ges like/imp like MDR 3
1104 HNCH 28 5 5 11 27 15 44 3302 exoU− ges like XDR 3
1105 HNCH 2 4 5 3 1 6 11 357 exoU− ges like XDR* 3
1115 HNCH 16 5 11 146 3 4 14 1751 exoU− − MR 3
1107 HAL 7 5 7 3 4 1 7 3305 exoU− − PS 4
1109 HAL 244 10 5 5 11 4 7 3301 exoU− − PS 1
1084 HAL 28 5 30 3 4 20 1 699 exoU− imp like MDR 2
1118 HAL 38 11 5 13 1 2 4 235 exoU− − MR 3
1119 HAL 6 5 6 5 4 4 7 641 exoU− − XDR 1
Table 6. Distribution of Multi-Locus Sequence Typing and exoU+/exoS+ genotype. HAL: Hospital Arzobispo 
Loayza, HNCH: Hospital Nacional Cayetano Heredia. New alleles and new sequence types described in this 
study are highlighted in bold. (−) negative phenotype. PS: Pan-susceptible; MR: Moderately drug-resistant; 
MDR: Multi drug-resistant. XDR: Extensively drug-resistant. XDR*: isolates resistant to all the antimicrobial 
agents tested except colistin. (1) wound/abscesses, (2) urine, (3) bronchial secretion, (4) catheter, (5) sputum.
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Bacterial isolates. One hundred eighty-nine non-duplicated P. aeruginosa clinical isolates were recovered 
from December 2012 to June 2013 in two Peruvian hospitals in the course of a previous study23. Of these, 77 iso-
lates were from the HAL and 112 from the HNCH.
Amplified 
product Primers Sequence (5′ → 3′)
Amplicon 
size (bp)
Annealing 
Temperature Ref.
Type III secretion system
   exoU
exoU - F ATG CAT ATC CAA TCG TTG
2000 58 °C 65
exoU - R TCA TGT GAA CTC CTT ATT
   exoS
exoS - F GCG AGG TCA GCA GAG TAT CG
118 58 °C 65
exoS - R TTC GGC GTC ACT GTG GAT
   exoT
exoT - F AAT CGC CGT CCA ACT GCA TGC G
152 58 °C 65
exoT - R TGT TCG CCG AGG TAC TGC TC
   exoY
exoY - F CGG ATT CTA TGG CAG GGA GG
289 58 °C 65
exoY - R GCC CTT GAT GCA CTC GAC CA
Quinolone resistance determining region of gyrA/parC and efflux pumps regulators
   gyrA
gyrA - F TTA TGC CAT GAG CGA GCT GGG CAA CGA CT
364 57 °C 61
gyrA - R AAC CGT TGA CCA GCA GGT TGG GAA TCT T
   parC
parC - F ATG AGC GAA CTG GGG CTG GAT
208 57 °C 61
parC - R ATG GCG GCG AAG GAC TTG GGA
   mexZ
mexZ - F CCA GCA GGA ATA GGG CGA CCA GGG C
1059 64 °C 61
mexZ - R CAG CGT GGA GAT CGA AGG CAG CCG G
   nfxB
nfxB - F CGC CCC GAT CCT TCC TAT T
924 64 °C 61
nfxB - R ACG AGC GTC ACG GTC CTT T
Metallo-β-lactamases
   imp
IMP - F GGA ATA GAG TGG CTT AAY TCT C
188 55 °C 66
IMP - R CCA AAC YAC TAS GTT ATC T
   vim
VIM - F GAT GGT GTT TGG TCG CAT A
390 55 °C 66
VIM - R CGA ATG CGC AGC ACC AG
   gim
GIM - F TCG ACA CAC CTT GGT CTG AA
477 55 °C 66
GIM - R AAC TTC CAA CTT TGC CAT GC
   spm
SPM - F AAA ATC TGG GTA CGC AAA CG
271 55 °C 66
SPM - R ACA TTA TCC GCT GGA ACA GG
   sim
SIM - F TAC AAG GGA TTC GGC ATC G
570 55 °C 66
SIM - R TAA TGG CCT GTT CCC ATG TG
Serine-carbapenemases
   kpc
KPC - F GTA TCG CCG TCT AGT TCT GC
636 55 °C 67
KPC - R GGT CGT GTT TCC CTT TAG CC
   imi
IMI - F ATA GCC ATC CTT GTT TAG CTC
818 55 °C 68
IMI - R TCT GCG ATT ACT TTA TCC TC
   ges
GES - F GTT TTG CAA TGT GCT CAA CG
371 55 °C 68
GES - R TGC CAT AGC AAT AGG CGT AG
Multi-locus sequence typing
   acsA
acsa - F ACC TGG TGT ACG CCT CGC TGA C
524 60 °C 45
acsA - R AGG TTG CCG AGG TTG TCC AC
   aroE
aroE - F TGG GGC TAT GAC TGG AAA CC
1053 60 °C 45
aroE - R TAA CCC GGT TTT GTG ATT CCT ACA
   guaA
guaA - F CGG CCT CGA CGT GTG GAT GA
673 60 °C 45
guaA - R GAC GTT GTG GTG CGA CTT GA
   mutL
mutL - F AGA AGA CCG AGT TCG ACC AT
705 60 °C
45
mutL - R GGG TAT AGG CGG AAT AGC C This Study
   nuoD
nuoD - F GCT TCA AGC CGG AAG ACT GG
438 60 °C
This Study
nuoD - R TGG CGG TCG GTG AAG GTG AA 45
   ppsA
ppsA - F GGT CGC TCG GTC AAG GTA GTG G
556 60 °C 45
ppsA - R GTA TCG CCT TCG GCA CAG GA
   trpE
trpE - F TTC AAC TTC GGC GAC TTC CA
603 60 °C 45
trpE - R CCC GGC GCT TGT TGA TGG TT
Table 7. Primers used in the study bp: basepair; Ref: Reference; F: Forward; R: Reverse.
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Different characteristics were analysed previously, including clonal relationships, biofilm production, bac-
terial motility and antimicrobial resistance23. The clonal relationships were determined using DNA fingerprint-
ing of all isolates which were generated by BOX-PCR analysis (Supplementary Figure)23. Finally, antimicrobial 
susceptibility to cephalosporins [ceftazidime, cefepime], monobactams [aztreonam], β-lactams+ inhibitors 
[piperacillin-tazobactam], carbapenems [imipenem, meropenem], aminoglycosides [gentamicin, tobramy-
cin, amikacin], FQs [ciprofloxacin, levofloxacin and ofloxacin] and polymyxins [colistin] has been previously 
reported according to the CLSI guidelines23,59. Antibiotics were grouped in the above indicated categories accord-
ing to Magiorakos et al.60 PS was defined as susceptibility to all the antimicrobial agents tested. MR was defined 
as non-susceptibility to at least 1 antibacterial agent of 1 or 2 antimicrobial categories. MDR was defined as 
non-susceptibility to at least 1 antimicrobial agent of three or more antimicrobial categories. XDR was defined as 
non-susceptibility to at least 1 antimicrobial agents in all but 2 or fewer antimicrobial categories.
Detection of T3SS genes by PCR. The presence of the exoS, exoT, exoU and exoY genes was determined 
by PCR with the primers and conditions shown in Table 6. To confirm the reliability of the results, exoS (from 
exoU−/exoS+ isolates) as well as exoY and exoT amplified products were randomly selected, recovered and 
sequenced. Regarding exoU+/exoS+ genotype, a representative isolate from each unrelated BOX-pattern was 
selected and both genes were sequenced. The exoS, exoT, and exoY were compared with that of the P. aeruginosa 
PAO1 (GenBank accession no.AE004091). Meanwhile, the exoU gene was compared with that of the P. aerugi-
nosa PA103 (GenBank accession no. AAC16023). In order to prevent the misidentification of the sought T3SS 
genes related to the high degree of sequence identity among these genes, all the primers were in silico tested pre-
viously against all T3SS effectors and with the full genome of the PAO1 strain.
Analysis of the quinolone resistance determining region of gyrA/parC. The amplification of the 
quinolone resistance determining region (QRDR) of gyrA and parC was performed by PCR (Table 6). All the 
PCR products were sequenced and the QRDR of the gyrA and parC genes were compared with those of the P. 
aeruginosa PAO1 reference strain.
Analysis of oprD and efflux regulator genes. The amplification of the oprD and the efflux 
regulator-encoding genes mexR, nalC, nalD, mexT and mexS were reported in a previous study17. The amplification 
of the nfxB and mexZ genes was performed with the primers designed by Solé et al.61, with slight modifications of the 
annealing conditions (Table 6). All the PCR products were recovered and sequenced as above. The nfxB and mexZ 
genes were compared with those of P. aeruginosa PAO1. Overall, amino acid substitutions, insertions and deletions 
were considered as an “Irrelevant modification” and frameshifts, premature STOPs, and no amplification of PCR 
genes was considered as a “Relevant modification” following the criteria previously described by Horna et al.17.
β-lactamases gene detection. The presence of metallo-β-lactamases and serine-carbapenemases was 
determined in all the isolates by means of EDTA and boronic acid combined disc tests, respectively62–64. In those 
isolates in which the use of EDTA or boronic acid showed an increase in the disc diameter halo ≥ 5 mm, the pres-
ence of metallo-β-lactamases (blaIMP, blaGIM, blaSIM, blaSPM and blaVIM) and serine-carbapenemases (blaIMI, blaGES 
and blaKPC) was determined by PCR. Amplified products were randomly selected, recovered and sequenced as 
above. Table 6 shows the annealing temperature, which was slightly modified in some cases.
Multi-locus sequence typing. A subset of 25 isolates, from the 50 for which data of antimicrobial resist-
ance mechanisms were available, were typed using MLST. This assay was performed according to that described 
in the MLST database website (https://pubmlst.org/paeruginosa/) with slight modifications (Table 7). Thus, 13 
exoU+ isolates and 12 randomly selected exoU− isolates were included in this analysis. All PCR products were 
purified, sequenced and thereafter compared with the allele sequences stored in the MLST database in order to 
establish the specific alleles and STs. All the isolates analysed, as well as newly detected alleles/ST profiles, were 
submitted to https://pubmlst.org/paeruginosa/ and are reported accordingly throughout the text.
statistical analysis. The χ2 test was used for statistical analysis. P values ≤ 0.05 were considered significant. 
The R study version 3.4.0. was used to perform the statistical analysis. Resistant and intermediate isolates were 
classified together as “non-susceptible” for statistical analyses.
Compliance with ethical standards. The study was approved by the Ethical Committee of the Universidad 
Peruana Cayetano Heredia (Lima, Peru) and by the Ethical Committee of Hospital Clinic (Barcelona, Spain), and 
all experiments were performed in accordance with relevant guidelines. All samples were obtained within routine 
clinical practice; no personal data was requested or available to researchers.
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable request.
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